HAIFA, Israel, March 12, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that it has initiated the process of scaling up the Company's manufacturing bioreactors from their current size of 5 liter (L) to 15L. The up scaling process is being coordinated to go on-line as part of Pluristem's current plant expansion. With the completion of the scaling up process, Pluristem will be positioned to become the leading manufacturer of cells for a variety of product candidates.
